Senhwa Biosciences Secures Strategic Backing from Global Investor GEM with Up to NT$500 Million to Accelerate AI-Driven Drug Development

/PRNewswire/ — Senhwa Biosciences, Inc. (TPEx: 6492), a clinical-stage biopharmaceutical company announced today the signing of a Memorandum of Understanding…Read More